KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Issuances: 2020-2024

Historic Long-Term Debt Issuances for AbCellera Biologics (ABCL) over the last 2 years, with Sep 2024 value amounting to $3.1 million.

  • AbCellera Biologics' Long-Term Debt Issuances fell 52.71% to $3.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $14.2 million, marking a year-over-year increase of 140.84%. This contributed to the annual value of $872,000 for FY2021, which is 94.37% down from last year.
  • Latest data reveals that AbCellera Biologics reported Long-Term Debt Issuances of $3.1 million as of Q3 2024, which was up 30.72% from $2.4 million recorded in Q2 2024.
  • In the past 5 years, AbCellera Biologics' Long-Term Debt Issuances ranged from a high of $16.2 million in Q1 2020 and a low of -$662,000 during Q2 2020.
  • Its 2-year average for Long-Term Debt Issuances is $3.5 million, with a median of $2.7 million in 2024.
  • Data for AbCellera Biologics' Long-Term Debt Issuances shows a maximum YoY plummeted of 52.71% (in 2024) over the last 5 years.
  • AbCellera Biologics' Long-Term Debt Issuances (Quarterly) stood at -$26,000 in 2020, then reached $6.6 million in 2023, then tumbled by 52.71% to $3.1 million in 2024.
  • Its last three reported values are $3.1 million in Q3 2024, $2.4 million for Q2 2024, and $2.1 million during Q1 2024.